The role of fibrates in a statin world

被引：15

作者：

Bloomfield, HE ^{[1
]}

机构：

[1] Vet Adm Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55417 USA

来源：

ARCHIVES OF INTERNAL MEDICINE | 2006年 / 166卷 / 07期

关键词：

D O I：

10.1001/archinte.166.7.715

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：715 / 716

页数：2

共 10 条

[1] HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE [J].

FRICK, MH ;

ELO, O ;

HAAPA, K ;

HEINONEN, OP ;

HEINSALMI, P ;

HELO, P ;

HUTTUNEN, JK ;

KAITANIEMI, P ;

KOSKINEN, P ;

MANNINEN, V ;

MAENPAA, H ;

MALKONEN, M ;

MANTTARI, M ;

NOROLA, S ;

PASTERNACK, A ;

PIKKARAINEN, J ;

ROMO, M ;

SJOBLOM, T ;

NIKKILA, EA .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (20) :1237-1245

[2] Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial [J].

Keech, A ;

Simes, RJ ;

Barter, P ;

Best, J ;

Scott, R ;

Taskinen, MR ;

Forder, P ;

Pillai, A ;

Davis, T ;

Glasziou, P ;

Drury, P ;

Kesäniemi, YA ;

Sullivan, D ;

Hunt, D ;

Colman, P ;

d'Emden, M ;

Whiting, M ;

Ehnholm, C ;

Laakso, M .

LANCET, 2005, 366 (9500) :1849-1861

[3] Insulin resistance and cardiovascular events with low HDL cholesterol - The Veterans Affairs HDL Intervention Trial (VA-HIT) [J].

Robins, SJ ;

Rubins, HB ;

Faas, FH ;

Schaefer, EJ ;

Elam, MB ;

Anderson, JW ;

Collins, D .

DIABETES CARE, 2003, 26 (05) :1513-1517

[4] Diabetes, plasma insulin, and cardiovascular disease - Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) [J].

Rubins, HB ;

Robins, SJ ;

Collins, D ;

Nelson, DB ;

Elam, MB ;

Schaefer, EJ ;

Faas, FH ;

Anderson, JW .

ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (22) :2597-2604

[5] Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol [J].

Rubins, HB ;

Robins, SJ ;

Collins, D ;

Fye, CL ;

Anderson, JW ;

Elam, MB ;

Faas, FH ;

Linares, E ;

Schaefer, EJ ;

Schectman, G ;

Wilt, TJ ;

Wittes, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (06) :410-418

[6] Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease - The bezafibrate infarction prevention (BIP) study [J].

Schlesinger, Z ;

Vered, Z ;

Friedenson, A ;

Reisin, L ;

Jafari, J ;

Flieb, T ;

Sclarovsky, S ;

Friedman, Y ;

Ostfeld, B ;

Solodky, A ;

Abinader, E ;

Rochfleish, S ;

Palant, A ;

Schneider, H ;

Rosenfeld, T ;

Khalid, S ;

Wolfson, E ;

Kishon, Y ;

Narinsky, R ;

Rotzak, R ;

Davidov, A ;

Levine, G ;

Zahavi, I ;

Vitrai, J ;

Diker, D ;

Pelled, B ;

Pardu, J ;

Galamidi, J ;

Majadla, R ;

Laniado, S ;

Sherf, L ;

Braun, S ;

Eschar, Y ;

Caspi, A ;

Arditi, A ;

Botwin, S ;

Arkavi, L ;

Ziv, M ;

David, D ;

Weisenberg, D ;

Kohanovski, M ;

Meisel, S ;

Rougin, N ;

Yahalom, M ;

Glusman-Vazan, A ;

Markiewitz, W ;

Motlak, D ;

Lessick, J ;

Kagan, G ;

Marmour, A .

CIRCULATION, 2000, 102 (01) :21-27

[7] Therapeutic roles of peroxisome proliferator-activated receptor agonists [J].

Staels, B ;

Fruchart, JC .

DIABETES, 2005, 54 (08) :2460-2470

[8] Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate [J].

Tenenbaum, A ;

Fisman, EZ ;

Boyko, V ;

Benderly, M ;

Tanne, D ;

Haim, M ;

Matas, Z ;

Motro, M ;

Behar, S .

ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (07) :737-741

[9] SOME CORONARY RISK-FACTORS RELATED TO THE INSULIN-RESISTANCE SYNDROME AND TREATMENT WITH GEMFIBROZIL - EXPERIENCE FROM THE HELSINKI HEART-STUDY [J].

TENKANEN, L ;

MANTTARI, M ;

MANNINEN, V .

CIRCULATION, 1995, 92 (07) :1779-1785

[10] Gemfibrozil in the treatment of dyslipidemia -: An 18-year mortality follow-up of the Helsinki Heart Study [J].

Tenkanen, L ;

Mänttäri, M ;

Kovanen, PT ;

Virkkunen, H ;

Manninen, V .

ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (07) :743-748

← 1 →